Waarom staat het aandeel OctoPlus vandaag ineens soms 50% hoger?

Er kwam wel positief nieuws naar buiten maar dat was eergister. Vandaag schiet het aandeel ineens de lucht in

Ik weet dat ze een nieuw contract hebben, ik snap alleen de stijging niet omdat de 6e en 7e het nieuws ook bekend was en er toen weinig gebeurde met octoplus

Weet jij het antwoord?

/2500

Het beste antwoord

Nieuw contract dus hoop op meer winst in de toekomst dus zullen de aandelen (waarschijnlijk) in de toekomst (fors) stijgen. :) OctoPlus wins new drug delivery evaluation contract 06.04.2009, Leiden, the Netherlands As part of the Company’s strategic focus on developing controlled release formulations for clients, OctoPlus N.V. (“OctoPlus” or “the Company”) (Euronext: OCTO) announces today that it has signed a new drug delivery technology evaluation contract with a European biotech company. This is the seventh client for which OctoPlus will work on a controlled release formulation. In October last year OctoPlus announced a strategic focus on developing controlled release versions of existing or new drugs for clients, in addition to providing general formulation development and clinical material manufacturing. Under the contract announced today, OctoPlus will evaluate the feasibility of a controlled release formulation that combines the active ingredient of the client with OctoPlus’ proprietary drug delivery technology. If the evaluation is successful, the contract may progress to a full process development, manufacturing and licensing agreement. For further information, please contact: Rianne Roukema, Corporate Communications, telephone number +31 (71) 524 1071 or e-mail IR@octoplus.nl. About OctoPlus OctoPlus is a product-oriented biopharmaceutical company committed to the creation of improved pharmaceutical products that are based on OctoPlus’ proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines on behalf of its clients. The lead product incorporating our technology is Locteron®, a controlled release formulation of interferon alfa for the treatment of chronic hepatitis C, which has been licensed to Biolex Therapeutics and is being manufactured by OctoPlus. Locteron is currently in Phase II clinical studies. In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

Misschien is de handel een dag stilgelegd in dit aandeel

misschien mensen met voorkennis, of mensen die vertrouwen hebben in het aandeel

Stel zelf een vraag

Ben je op zoek naar het antwoord die ene vraag die je misschien al tijden achtervolgt?

/100